Complex and Customized: Manufacturing New Molecular Formats
Increasingly complex monoclonal antibody molecules will require the right “tool box” for scaling up manufacturing.
Now that high yields have been achieved for the first generation of monoclonal antibodies, the next challenge will be developing ways to produce larger quantities of even more complex antibody formats. These increasingly complex molecules will require the right “tool box” for scaling up manufacturing.
Read this article in BioPharm International's Outsourcing Resources 2019 eBook.
Article Details
BioPharm International
eBook: Outsourcing Resources 2019
April 2019
Pages: 16–19
Citation
When referring to this article, please cite it as Andy Racher, "Complex and Customized: Manufacturing New Molecular Formats,"BioPharm International's Outsourcing Resources eBook (April 2019).
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.
